Inhibition of peripheral interleukin-1β-induced hyperalgesia by the intracerebroventricular administration of diclofenac and α-melanocyte-stimulating hormone

Takakazu Oka, Kae Oka, Masako Hosoi, Tetsuro Hori

Research output: Contribution to journalArticle

16 Citations (Scopus)


The present study was undertaken to investigate whether or not the endogeneous mechanisms in the brain can modulate the changes in nociception produced by peripherally-administered interleukin-1β (IL-1β) in rats. We administered diclofenac and α-melanocyte-stimulating hormone (α-MSH) into the lateral cerebroventricle (LCV) 10 min before the intraperitoneal (i.p.) injection of recombinant human IL-1β (rhIL-1β, 1 ng/kg-100 ng/kg) and then observed the changes in nociception using a hot-plate test. The i.p. injection of rhIL-1β (10 ng/kg and 100 ng/kg) reduced the paw-withdrawal latency without affecting the colonic temperature. The maximal reduction in the paw-withdrawal latency was observed 30 min after the i.p. injection of rhIL-1β at 100 ng/kg. The rhIL-1β (100 ng/kg)-induced hyperalgesia was inhibited by the LCV injection of both diclofenac (1 ng) and α-MSH (100 ng). The LCV injection of either diclofenac (1 ng) or α-MSH (100 ng) was found to have no effect on nociception by itself. These findings therefore suggest that the hyperalgesia induced by peripheral IL-1β can be modulated by a cyclooxygenase pathway of the arachidonate and α-MSH in the brain.

Original languageEnglish
Pages (from-to)237-242
Number of pages6
JournalBrain Research
Issue number1-2
Publication statusPublished - Oct 14 1996


All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Molecular Biology
  • Clinical Neurology
  • Developmental Biology

Cite this